Clinical Trial Update: Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease [Phase 1]

View source ↗

Summary

Phase 1 trial update for guselkumab in alcoholic liver disease; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcoholic Liver Disease

Drugs mentioned

• TREMFYA (guselkumab)

Snippet

Sponsor: University of California, San Diego | Conditions: Alcoholic Liver Disease | Phase 1 | Status: COMPLETED